Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Completed 2Not yet recruiting 1

Sponsor Class

OTHER 12INDUSTRY 3NIH 2NETWORK 2

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Genitourinary 1

Conditions

Disease 2Brain Neoplasms 2Prostatic Neoplasms 1

Interventions

pembrolizumab 610Carboplatin 375Paclitaxel 283Cisplatin 268Gemcitabine 256Pemetrexed 194Bevacizumab 191Nivolumab 190Docetaxel 190Injections 169Cyclophosphamide 148atezolizumab 138Capecitabine 134Fluorouracil 133Oxaliplatin 132Dexamethasone 129Fulvestrant 115durvalumab 114130-nm albumin-bound paclitaxel 111fludarabine 102Cetuximab 101Leucovorin 97Rituximab 96venetoclax 90Lenalidomide 84Prednisone 79enzalutamide 78Azacitidine 76Irinotecan 74Ipilimumab 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × fluciclovine F-18 × 1 year × Clear all
NCT07569926 2026-06-02

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

Blue Earth Diagnostics

Phase 4 Not yet recruiting
142 enrolled
Genitourinary

Prostatic Neoplasms

NCT04410133 2025-08-28

REVELATE

Blue Earth Diagnostics

Phase 3 Completed
151 enrolled 29 charts
CNS

Brain Neoplasms, Disease

NCT04410367 2025-07-20

PURSUE

Blue Earth Diagnostics

Phase 2 Completed
23 enrolled 10 charts
CNS

Brain Neoplasms, Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡